CMS Open Payments · Program Year 2024
ConvaTec Inc.
ConvaTec Inc. reported $9,304,323.30 across General Payments, Research, and Ownership to 12,574 physicians and teaching hospitals across 12,607 transactions.
- $9.3M Top 10% payer
- All-tracks total
- 12,607 Top 10% volume
- Transactions
- 12,574 Top 10% reach
- Recipients
- +$7.5M
- General Payments vs PY2023
ConvaTec Inc. reported $9,304,323.30 across all CMS Open Payments tracks (General + Research + Ownership) to 12,574 physicians and teaching hospitals in Program Year 2024 - ranking #183 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $8,497,216.63, averaging $739.97 per recipient.
How ConvaTec Inc.'s $9.3M all-tracks total breaks down
ConvaTec Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
93/100
Total payments
A
96/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer convatec-inc ConvaTec Inc.
$9.3M · #183/1,925 · 0.1% industry · PY2024
- TOT $9.3M
- RANK #183
- SHARE 0.1%
- TXN 12,607
- RCP 12,574
- CAT 6
- GEN $8.5M
- ΔGEN +$7.5M
- TOP1 9.6%
- PY 2024
Volume peers
Nearest volume peer: Eli Lilly Export S.A. Puerto Rico Branch ($9.2M)
ConvaTec Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ConvaTec Inc.'s CMS-reported General Payments increased by $7.5M (+772.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CONVATEC INC.PY2023: CONVATEC INC.PY2024: ConvaTec Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $974,068.85
- PY2024
- $8,497,216.63
What the Data Shows for ConvaTec Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For ConvaTec Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
1,241 transactions worth $6.8M make "Debt Forgiveness" the top general-payment category in the 6-category breakdown below, 80.6% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 6 types of general payments, ConvaTec Inc.'s largest category was "Debt Forgiveness" at $6.8M - 80.6% of General Payments.
ConvaTec Inc. reports 6 general-payment categories - the top three are Debt Forgiveness (80.6%), Consulting Fee (10.8%), and Food and Beverage (5.0%). The remaining 3 categories make up 3.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How ConvaTec Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Debt Forgiveness | $6.8M | 1,241 | 80.6% |
| Consulting Fee | $915.1K | 251 | 10.8% |
| Food and Beverage | $425.4K | 10,402 | 5.0% |
| Travel and Lodging | $234.6K | 656 | 2.8% |
| Space Rental or Facility Fees | $76.3K | 23 | 0.9% |
| Grant | $251.65 | 1 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,352,640.00 (27.7%) of $8,497,216.63 in this company's General Payments records across 6,449 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ConvaTec Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Anton Dias Perera
$817,190.00 across 77 reported transactions
- 2
Naz Wahab
$446,150.00 across 9 reported transactions
- 3
Abdul Latif Nurudeen
$386,400.00 across 22 reported transactions
- 4
April Lopez
$386,100.00 across 49 reported transactions
- 5
Jonathan Johnson
$316,800.00 across 14 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
ConvaTec Inc. ranks #183 of 1,925 by total payments (top 10% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,500 of 1,838 by HHI (bottom 18% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Terumo Medical Corporation : $1.2M total payments, HHI 267
- Aveo Pharmaceuticals, Inc. : $486.7K total payments, HHI 267
- Escala Medical Inc. : $6.0K total payments, HHI 266
- Elucent Medical : $251.3K total payments, HHI 265
- AltaThera Pharmaceuticals LLC : $230.3K total payments, HHI 265
- Team 1, Llc : $78.3K total payments, HHI 263
- ConvaTec Inc. (this company) : $8.5M total payments, HHI 261
- Avita Medical Americas, Llc : $545.0K total payments, HHI 257
- Core Surgical Group : $20.0K total payments, HHI 256
- Curonix LLC : $754.8K total payments, HHI 254
- Argon Medical Devices, Inc. : $147.3K total payments, HHI 254
- Averitas Pharma Inc. : $1.5M total payments, HHI 253
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ConvaTec Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ConvaTec Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ConvaTec Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
W. L. Gore & Associates, Inc.
Hoffmann-La Roche Limited
Tarsus Pharmaceuticals, Inc.
Tyber Medical, LLC
4WEB, Inc.
Put this to use
ConvaTec Inc. ranks #183 of 1,925 by all-tracks total payments, led by "Debt Forgiveness".
- See where ConvaTec Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Debt Forgiveness" spend across every manufacturer, not just ConvaTec Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.